Losartan reduces sympathetic nerve outflow from the brain of rats with chronic renal failure

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 1, Issue 2, 2000, Pages 202-208

  Campese, Vito M ^a,b   Ye, Shaohua ^a   Truong, Rex H ^a   Gamburd, Michael ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b LAC USC MEDICAL CENTER   (United States)

Author keywords

Chronic renal failure; Interleukin 1 ; Losartan; Nitric oxide; Nitric oxide synthase; Posterior hypothalamus; Sympathetic nerve activity

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR; INTERLEUKIN 1; LOSARTAN; MESSENGER RNA; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; NORADRENALIN; NOS1 PROTEIN, RAT;

ADRENERGIC SYSTEM; ANIMAL; ARTICLE; BLOOD PRESSURE; BRAIN; CHRONIC KIDNEY FAILURE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; MALE; METABOLISM; PATHOPHYSIOLOGY; POSTERIOR HYPOTHALAMUS; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD PRESSURE; BRAIN; HYPOTHALAMUS, POSTERIOR; INTERLEUKIN-1; KIDNEY FAILURE, CHRONIC; LOSARTAN; MALE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; RNA, MESSENGER; SYMPATHETIC NERVOUS SYSTEM;

EID: 0034211312     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2000.026     Document Type: Article

References (53)

1. Schalekamp MADH, Schalekamp-Kuyken MPA, deMoor-Fruytier M, Meininger T, Vaandrager-Kranenburg DJ, Birkenhager WH. Interrelationships between blood pressure, renin, renin substrate and blood volume in terminal renal failure. Clin Sci Mol Med 1973;45:417-28.
2. Lazarus JM, Hampers CL, Merrill JP. Hypertension in chronic renal failure.Treatment with hemodialysis and nephrectomy. Arch Intern Med 1974; 133:1059-66.
3. Atuk NO, Bailey CJ, Turner S, Peach MJ, Westervelt FB, Jr. Red blood cell catechol-o-methyl transferase, plasma catecholamines and renin in renal failure. Trans Am Soc Artif Intern Organs 1976; 22:195-200.
4. Lake CR, Ziegler MG, Coleman MD, Kopin IJ. Plasma levels of norepinephrine and dopamine-beta-hydroxylase in CRF patients treated with dialysis. Cardiovasc Med 1979; 1:1099-1111.
5. Henrich WL, Katz FH, Molinoff PB, Schrier RW. Competitive effects of hypokalemia and volume depletion on plasma renin activity, aldosterone and catecholamine concentrations in hemodialysis patients.Kidney Int 1977;12:279-84.
6. Izzo JL, Izzo MS, Sterns RH, Freeman RB. Sympathetic nervous system hyperactivity in maintenance hemodialysis patients.Trans. Am Soc Artif Organs 1982; 28: 604-7.
7. Cuche JL, Prinseau J, Selz F, Ruget G, Baglin A. Plasma free, sulfo- and glucuro-conjugated catecholamines in uremic patients. Kidney Int 1986;30:566-72.
8. Bigazzi R, Kogosov E, Campese VM. Altered norepinephrine turnover in the brain of rats with chronic renal failure. J Am Soc Nephrol 1994;4:1901-7.
9. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 1997;51:722-7.
10. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25[part 2]:878-82.
11. Converse RL Jr., Jacobsen TN, Toto RD et al. Sympathetic overactivity in patients with CRF. New Engl J Med 1992;327:1912-8.
12. Ferrario CM, Gildenberg PL, McCubbin JW. Cardiovascular effects of angiotensin mediated by the central nervous system. Circ Res 1972:30:257-62.
13. Zimmerman BG, Sybertz EJ, Wong PC. Interaction between sympathetic and renin-angiotensin system. J Hypertens 1984;2:581-8.
14. McGiff JC, Fasy TM. The relationship of the renal vascular activity of angiotensin II to the autonomie nervous system. J Clin Invest 1965;4:1911-23.
15. Chiu AT, McCall DE, Price WA et al. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;252:711-8.
16. Wong PC, Price WA, Chiu AT et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174, an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;255:211-7.
17. Ohlstein EH, Gellai M, Brooks DP et al. The antihypertensive effects of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism. J Pharmacol Exp Ther 1992;262:595-601.
18. Brooks DP, Ohlstein EH, Ruffolo RR, Jr. Pharmacology of eprosartan, an angiotensin II receptor antagonist: Exploring hypotheses from clinical data. AM Heart J 1999;138:246-51.
19. Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neuronal role for nitric oxide. Nature 1990; 347:768-70.
20. Vincent SR, Kimura H. Histochemical mapping of nitric oxide synthase in the rat brain. Neuroscience 1992;46:755-84.
21. Tseng CJ, Liu HY, Lin HC, Ger LP, Tung CS, Yen MH. Cardiovascular effects of nitric oxide in the brain stem nuclei of rats. Hypertension 1996;27:36-42.
22. Sander M, Hansen PG, Victor RG. Sympathetically mediated hypertension caused by chronic inhibition of nitric oxide. Hypertension 1995;26:691-5.
23. Matsuoka H, Nishida H, Nomura G, van Vliet BN, Toshima H. Hypertension induced by nitric oxide synthesis inhibition is renal nerve dependent. Hypertension 1994;23[part 2]:971-5.
24. Yee S, Nosrati S, Campese VM. Nitric oxide (NO) modulates the neurogenic control of blood pressure in rats with chronic renal failure. J Clin Invest 1997;99:540-8.
25. Ye S, Mozayeni P, Gamburd M, Zhong H, Campese VM. Interleukin 1-ß and the neurogenic control of blood pressure in normal rats and rats with chronic renal failure. Am J Physiol (In press).
26. Bigazzi R, Kogosov E, Campese VM. Altered norepinephrine turnover in the brain of rats with chronic renal failure. J Am Soc Nephrol 1994;4:1901-7.
27. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. New York: Academic 1986.
28. 3H] dopa in various regions of the brain. J Neurochem 1966;13: 665-9.
29. Palkovits M, Zaborszky L. Neuroanatomy of central cardiovascular control. In: W. de Jong, A.P. Provoost and A.P. Shapiro (Eds), Hypertension and Brain Mechanisms, Progress in Brain Research, Vol 47, Elsevier, Amsterdam, 1977:9-34.
30. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
31. Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 1991; 351:714-8.
32. Scotte M, Hiron M, Masson S. Differential expression of cytokine genes in monocytes, peritoneal macrophages and liver fllowing endotoxin-or turpentine-induced inflammation in rat. Cytokine 1996;8:115-20.
33. Higuchi R, Dollinger G. Simultaneous amplification and detection of specific DNA sequences. Biotechnology 1992; 10:413-7.
34. Patel KP, RL Kline. Influence of renal nerves on noradrenergic responses to changes in arterial pressure. Am J Physiol 1984;247:R615-20.
35. Chalmers JP. Brain amines and models of experimental hypertension. Circ Res 1975;36:469-80.
36. Patel KP, Kline RL. Influence of renal nerves on noradrenergic responses to changes in arterial pressure. Am J Physiol 1984;247:R615-20.
37. Chalmers JP. Brain amines and models of experimental hypertension. Circ Res 1975;36:469-80.
38. Bunag RD, Eferakeya AE. Immediate hypotensive after-effects of posterior hypothalamic lesions in awake rats with spontaneous, renal, or DOCA hypertension. Cardiovasc Res 1976;10:663-71.
39. Nakata T, Berard W, Kogosov E, Alexander N. Microdialysis in the posterior hypothalamus: sodium chloride affects norepinephrine release, mean arterial pressure, heart rate and behavior in awake rats. Brain Res Bull 1990;25:593-8.
40. Ruhl A, Hurst S, Collins SM. Synergism between interleukins 1β and 6 on noradrenergic nerves in rat myenteric plexus. Gastroenterology 1994;107:993-1001.
41. Ruhl A, Berezin I, Collins SM. Involvement of eicosanoids and macrophage-like cells in cytokine-mediated changes in rat myenteric nerves. Gastroenterology 1995;109:1852-62.
42. Ichijo T, Katafuchi T, Hori T. Central interleukin-1β enhances splenic sympathetic nerve activity in rats. Brain Res Bull 1994;34:547-53.
43. Terao A, Oikawa M, Saito M. Tissue-specific increase in norepinephrine turnover by central interleukin-1, but not by interleukin-6, in rats. Am J Physiol 1994;266:R400-4.
44. Niijima A, Hori T, Aou S, Oomura Y. The effects of interleukin-1β on the activity of adrenal splenic and renal sympathetic nerves in the tax. J Autonom Nerv Syst 1991;36:183-92.
45. Murakami Y, Yokotani K, Okuma Y, Osumi Y. Nitric oxide mediates central activation of sympathetic outflow induced by interleukin-1ß in rats. Europ J Pharmacol 1996;317:61-6.
46. Liu S, Adcock IM, Ols RW, Barnes PJ, Evans TW. Lipopolysaccharide treatment in vivo induces widespread tissue expression of inducible nitric oxide synthase mRNA. Biochem Biophys Res Commun 1993;196:1208-13.
47. Robbins RA, Springall DR, Warren JB et al. Inducible nitric oxide synthase is increased in murine lung epithelial cells by cytokine stimulation. Biochem Byophys Res Commun 1994;198:835-43.
48. Tanazawa T, Suzuki Y, Anzai M, Tsugane S, Takayasu M, Shibuya M. Vasodilation by intrathecal lipopolysaccharide of the cerebral arteries after subarachnoid haemorrhage in dogs. Acta Neurochir 1996;138:330-7.
49. Shibata AI, Parfenova H, Zuckerman SL, Seyer JM, Krueger JM, Leffler CW. Interleukin-1β peptides induce cerebral pial arteriolar dilation in anesthetised newborn pigs. Am J Physiol 1996;270:R1044-50.
50. Barnes PJ. NO or no NO in asthma? Thorax 1996;51: 218-20.
51. Bonmann E, Suschek C, Spranger M, Kolb-Bachofen V. The dominant role of exogenous interleukin-1 beta on expression and activity of inducible nitric oxide synthase in rat microvascular brain endothelial cells. Neurosci Lett 1997;230:109-12.
52. Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neuronal role for nitric oxide. Nature 1990;347:768-70.
53. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 1997;51:722-7.